Servier-Backed ARMGO Firm Takes on Heart Disease, More
By Randy Osborne
BioWorld Today Contributing Writer
BioWorld Today Contributing Writer
Thursday, September 27, 2012
CEO Sapan Shah calls ARMGO Pharma Inc. "one of biotech's better-kept secrets," but news about the company has begun to leak – not unlike the faulty calcium channels in diseased tissue that ARMGO's Phase II drug candidates are designed to fix.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries,
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2015 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter